Patent: 9,764,033
✉ Email this page to a colleague
Summary for Patent: 9,764,033
Title: | Formulation for anti-.alpha.4.beta.7 antibody |
Abstract: | Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-.alpha.4.beta.7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-.alpha.4.beta.7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-.alpha.4.beta.7 antibody in vivo. |
Inventor(s): | Diluzio; Willow (Westford, MA), Truong; Nobel T. (Milford, MA), Varga; Csanad M. (Cambridge, MA), Palaniappan; Vaithianathan (Andover, MA), Brown; Jason (Burlington, MA), Scholz; Catherine (Woburn, MA) |
Assignee: | Millennium Pharmaceuticals, Inc. (Cambridge, MA) |
Application Number: | 14/114,832 |
Patent Claims: | see list of patent claims |
Details for Patent 9,764,033
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Takeda Pharmaceuticals U.s.a., Inc. | ENTYVIO | vedolizumab | For Injection | 125476 | 05/20/2014 | ⤷ Try a Trial | 2031-05-02 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |